Within an incident T2D case–cohort study nested within the population-based EPIC-Norfolk study, a prospective cohort study recruiting 25,639 individuals, Cardona et al. [220] confirmed the results of [199], identifying 18 methylation variable positions in whole blood strongly associated with incident T2D, of which the most robust involved TXNIP (decreased methylation), ABCG1, and SREBF1 (both increased methylation). The gene discussed is SREBF1; the disease is type 2 diabetes mellitus.